Immunic's lead MS drug hits primary and key secondary endpoints in PhII, but questions remain
Just a week after its lead program began enrolling patients in a study to treat Covid-19, Immunic Therapeutics is making more waves.
This time, the …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
